These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35649145)

  • 1. The impact of the rare disease and Orphan Drug Act in Taiwan.
    Hsiang NC; Huang WF; Gau CS; Tsai TW; Chang LC
    J Food Drug Anal; 2021 Dec; 29(4):717-725. PubMed ID: 35649145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
    Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Incentive Policies and Initiatives on Orphan Drug Development in China: Challenges, Reforms and Implications.
    Zhao Z; Pei Z; Hu A; Zhang Y; Chen J
    Orphanet J Rare Dis; 2023 Jul; 18(1):220. PubMed ID: 37501126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient Access to Orphan Drugs Covered by Medical Insurance in China: Real-World Evidence From Patient Survey.
    Wang X; Li SC; Yue X; Li Y; Shi N; Zhao FL; Wu J
    Value Health Reg Issues; 2023 Mar; 34():71-77. PubMed ID: 36587572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis.
    Chan AYL; Chan VKY; Olsson S; Fan M; Jit M; Gong M; Zhang S; Ge M; Pathadka S; Chung CCY; Chung BHY; Chui CSL; Chan EW; Wong GHY; Lum TY; Wong ICK; Ip P; Li X
    Value Health; 2020 Dec; 23(12):1580-1591. PubMed ID: 33248513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic considerations in the provision of treatments for rare diseases.
    McCabe C; Edlin R; Round J
    Adv Exp Med Biol; 2010; 686():211-22. PubMed ID: 20824448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical assessment of belgian reimbursement dossiers of orphan drugs.
    Denis A; Mergaert L; Fostier C; Cleemput I; Hulstaert F; Simoens S
    Pharmacoeconomics; 2011 Oct; 29(10):883-93. PubMed ID: 21905759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Issues surrounding orphan disease and orphan drug policies in Europe.
    Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
    Appl Health Econ Health Policy; 2010; 8(5):343-50. PubMed ID: 20804226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How Far Have We Come? Challenges to Orphan Drug Access in China, 2011-2017.
    Guan X; Zhang J; Man C; Ni B; Shi L
    J Pharm Sci; 2019 Jun; 108(6):2199-2205. PubMed ID: 30677418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring alternative financing models and early access schemes for orphan drugs: a Belgian case study.
    Abdallah K; Claes K; Huys I; Follon L; Calis C; Simoens S
    Orphanet J Rare Dis; 2022 Dec; 17(1):429. PubMed ID: 36494733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient Accessibility and Budget Impact of Orphan Drugs in South Korea: Long-Term and Real-World Data Analysis (2007-2019).
    Lee SH; Yoo SL; Bang JS; Lee JH
    Int J Environ Res Public Health; 2020 Apr; 17(9):. PubMed ID: 32357397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Shift of focus in the financing of Hungarian drugs. Reimbursement for orphan drugs for treating rare diseases: financing of enzyme replacement therapy in Hungary].
    Szegedi M; Molnár MJ; Boncz I; Kosztolányi G
    Orv Hetil; 2014 Nov; 155(44):1735-41. PubMed ID: 25344850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the national system for rare diseases in China from the point of drug access: progress and challenges.
    Qiao L; Liu X; Shang J; Zuo W; Xu T; Qu J; Jiang J; Zhang B; Zhang S
    Orphanet J Rare Dis; 2022 Sep; 17(1):352. PubMed ID: 36088349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The urgent need to empower rare disease organizations in China: an interview-based study.
    Li X; Lu Z; Zhang J; Zhang X; Zhang S; Zhou J; Li B; Ou L
    Orphanet J Rare Dis; 2020 Oct; 15(1):282. PubMed ID: 33046132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.
    Stockklausner C; Lampert A; Hoffmann GF; Ries M
    Oncologist; 2016 Apr; 21(4):487-93. PubMed ID: 27022038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers.
    Karas L; Lu CY; Agrawal PB; Asgari MM
    J Am Acad Dermatol; 2019 Sep; 81(3):867-877. PubMed ID: 31103566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing treatments for inborn errors: incentives available to the clinician.
    Haffner ME
    Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [FINANCING OF MEDICINES FOR TREATMENT OF RARE DISEASES OF THE NERVOUS SYSTEM. ORPHAN DRUGS IN RARE NEUROLOGICAL DISEASES].
    Szegedi Márta ; Kosztolányi G; Boncz I; Molnár MJ
    Ideggyogy Sz; 2016 Jan; 69(1-2):37-45. PubMed ID: 26987239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.